Fresenius Acquires APP Pharmaceuticals (APPX) For $23/Share, Plus An Extra $6 If Results are Meet
More News related to APPX
- APP Pharmaceuticals (APPX) Reports Slightly Higher Q2 Earnings; Issues Soft FY08 Guidance
- Unusual 11 Mid-Day Movers 7/7: RDN, APPX, IGLD, MPG Higher; VRTU, ININ, FBN, OFIX Lower
- Pre-Open Movers 7/7: APP Pharmaceuticals (APPX) Up on Buyout; Marshall & Ilsley (MI) Lower After Predicting Large Q2 Loss
- Fresenius Acquires APP Pharmaceuticals (APPX) For $23/Share, Plus An Extra $6 If Results are Meet
- APP Pharmaceuticals (APPX) Receives Final Approval for Generic Kytril
APP Pharmaceuticals, Inc. (Nasdaq: APPX) and Fresenius SE (XETRA: FRE) entered into a definitive merger agreement pursuant to which Fresenius will acquire APP.
Under the terms of the agreement, Fresenius will acquire the outstanding common stock of APP for $23.00 in cash per share plus a contingent value right that could deliver up to an additional $970 million, or $6.00 per share in cash, if the financial results of the Company meet certain targets.
APP Pharmaceuticals closed at $17.82 on Friday.
Related Categories
Hot ListMergers and Acquisitions
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
